Guizhou Xinbang Pharmaceutical Co., Ltd.

002390.SZ

002390.SZGuizhou Xinbang Pharmaceutical Co., Ltd. CN flag

Shenzhen

3.53

CNY

+0.02

(+0.57%)

0.04EPS

88.25P/E

6.48BMarket Cap

Aug 28Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE100000NG5

Return %

Stock

S&P500

-11.53

8.32

-28.83

43.81

-20.50

96.82

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	0.52	0.68	2.22	3.36	3.14	3.57	4.06	4.22	3.71	3.56	3.4	3.37	- -	2.86
Basic EPS, GAAP	0.06	0.05	0.13	0.14	0.15	0.19	-0.8	0.15	0.11	0.15	0.12	0.15	- -	0.04
Free Cash Flow per Basic Share	-0.1	-0.08	-0.43	-0.22	-0.38	-0.14	-0.3	0.43	0.38	0.11	0.23	0.34	- -	-0.05
Dividend per Share	0.03	0.03	0.08	0.12	0.11	0.11	0.16	0.13	0.13	0.13	0.09	0.08	- -	0.09
Book Value per Share	0.46	0.5	0.78	1.41	1.47	1.59	0.8	0.97	1.07	1.26	1.24	1.29	- -	1.18
Tangible Book Value per Share	1.12	1.15	1.5	1.49	2.33	2.44	2.51	2.52	2.75	3.3	3.34	3.32	- -	3.01
Basic Weighted Avg Shares	854	838	1,114	1,246	1,640	1,681	1,621	1,575	1,577	1,819	1,870	1,915	- -	2,062
Sales/Revenue/Turnover	448	569	2,476	4,180	5,157	6,002	6,580	6,655	5,846	6,472	6,350	6,461	6,032	5,891
Operating Margin (%)	10.76	8.39	9.73	7.31	7.68	8.77	7.67	7.83	7.7	8.74	5.99	7.18	5.68	5.45
Depreciation Expense	8	20	50	127	150	175	215	238	232	247	244	237	218	- -
Net Income, GAAP	48	40	145	174	246	319	-1,297	236	174	273	224	287	101	84
Effective Tax Rate (%)	17.08	16.96	22.7	26.2	22.21	20.91	- -	20.44	17.53	11.2	14.4	10.67	16.07	17.45
Profit Margin (%)	10.69	7.07	5.85	4.17	4.77	5.32	-19.7	3.55	2.97	4.22	3.53	4.45	1.68	1.42
Working Capital	655	627	616	55	1,358	1,464	1,336	1,166	1,621	2,822	3,119	3,353	3,445	3,528
LT Debt	- -	- -	14	16	- -	298	323	299	25	25	22	21	181	249
Total Equity	1,023	1,036	2,458	2,669	6,485	6,759	5,169	5,048	5,169	6,829	7,065	7,142	7,020	7,001
Return on Invested Capital (%)	3.3	3.05	6.63	4.86	4.32	4.24	- -	4.62	4.34	6.11	4.02	5.23	3.71	3.36
Return on Capital (%)	9.8	7.98	11.07	7.8	7.32	6.61	- -	6.07	3.85	5.64	5.74	6.8	1.89	1.37
Return on Common Equity (%)	12.81	9.99	22.57	13.29	11.82	12.59	-65.26	16.72	10.79	13.66	9.72	11.99	4.16	3.37

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	11.11%	-1.64%	-6.63%
Net Income, GAAP	-55.66%	-4.75%	-64.7%
Free Cash Flow	-4.69%	12.77%	-22.1%
Total Cash Common Dividend	11.17%	0.13%	21.53%
Total Equity	16.73%	7.47%	-1.71%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Ms. Lingzhong Kong
Full Time Employees: 5,059
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: Intersection of Hangtian Avenue and Xint Guiyang People's Republic of China 550018
IPO Date: Apr 16, 2010
Website: xinbang.com
Similar Companies: Petlife Pharmaceuticals, Inc. (PTLF)
PeakBirch Commerce Inc. (PKBFF)
CanSino Biologics Inc. (CASBF)
Suven Pharmaceuticals Limited (SUVENPHAR.BO)
Targeted Medical Pharma, Inc. (TRGM)
Aurobindo Pharma Limited (AUROPHARMA.NS)
Business: Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.

	Sep'24	Dec'24	Mar'25
Total Current Assets	5,143	5,252	5,275
Accounts Receivable, Net	2,716	2,534	2,596
Cash, Cash Equivalents & STI	752	1,016	985
Inventories	924	1,060	1,015
Total Current Liabilities	1,759	1,807	1,747
Payables & Accruals	- -	- -	- -
ST Debt	613	595	554
Deferred Revenue	- -	- -	- -

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	0.52	0.68	2.22	3.36	3.14	3.57	4.06	4.22	3.71	3.56	3.4	3.37	- -	2.86
Basic EPS, GAAP	0.06	0.05	0.13	0.14	0.15	0.19	-0.8	0.15	0.11	0.15	0.12	0.15	- -	0.04
Free Cash Flow per Basic Share	-0.1	-0.08	-0.43	-0.22	-0.38	-0.14	-0.3	0.43	0.38	0.11	0.23	0.34	- -	-0.05
Dividend per Share	0.03	0.03	0.08	0.12	0.11	0.11	0.16	0.13	0.13	0.13	0.09	0.08	- -	0.09
Book Value per Share	0.46	0.5	0.78	1.41	1.47	1.59	0.8	0.97	1.07	1.26	1.24	1.29	- -	1.18
Tangible Book Value per Share	1.12	1.15	1.5	1.49	2.33	2.44	2.51	2.52	2.75	3.3	3.34	3.32	- -	3.01
Basic Weighted Avg Shares	854	838	1,114	1,246	1,640	1,681	1,621	1,575	1,577	1,819	1,870	1,915	- -	2,062
Sales/Revenue/Turnover	448	569	2,476	4,180	5,157	6,002	6,580	6,655	5,846	6,472	6,350	6,461	6,032	5,891
Operating Margin (%)	10.76	8.39	9.73	7.31	7.68	8.77	7.67	7.83	7.7	8.74	5.99	7.18	5.68	5.45
Depreciation Expense	8	20	50	127	150	175	215	238	232	247	244	237	218	- -
Net Income, GAAP	48	40	145	174	246	319	-1,297	236	174	273	224	287	101	84
Effective Tax Rate (%)	17.08	16.96	22.7	26.2	22.21	20.91	- -	20.44	17.53	11.2	14.4	10.67	16.07	17.45
Profit Margin (%)	10.69	7.07	5.85	4.17	4.77	5.32	-19.7	3.55	2.97	4.22	3.53	4.45	1.68	1.42
Working Capital	655	627	616	55	1,358	1,464	1,336	1,166	1,621	2,822	3,119	3,353	3,445	3,528
LT Debt	- -	- -	14	16	- -	298	323	299	25	25	22	21	181	249
Total Equity	1,023	1,036	2,458	2,669	6,485	6,759	5,169	5,048	5,169	6,829	7,065	7,142	7,020	7,001
Return on Invested Capital (%)	3.3	3.05	6.63	4.86	4.32	4.24	- -	4.62	4.34	6.11	4.02	5.23	3.71	3.36
Return on Capital (%)	9.8	7.98	11.07	7.8	7.32	6.61	- -	6.07	3.85	5.64	5.74	6.8	1.89	1.37
Return on Common Equity (%)	12.81	9.99	22.57	13.29	11.82	12.59	-65.26	16.72	10.79	13.66	9.72	11.99	4.16	3.37

Year	Q1	Q2	Q3	Q4	FY
2023	1,605	1,651	1,567	1,638	6,461
2024	1,582	1,464	1,519	1,467	6,032
2025	1,441	- -	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	613	595	554
LT Borrowings	- -	160	230
LT Finance Leases	19	21	19
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	1,944	1,944	1,944
Market Capitalization	7,157	8,922	7,671

Guizhou Xinbang Pharmaceutical Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Capital Structure